Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) EBITDA Margin (2016 - 2025)

Fate Therapeutics (FATE) has disclosed EBITDA Margin for 14 consecutive years, with 2367.49% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 46691.0% year-over-year to 2367.49%, compared with a TTM value of 2053.37% through Dec 2025, down 68877.0%, and an annual FY2025 reading of 2053.37%, down 68877.0% over the prior year.
  • EBITDA Margin was 2367.49% for Q4 2025 at Fate Therapeutics, down from 1847.16% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 29.96% in Q1 2023 and bottomed at 5648.02% in Q2 2023.
  • Average EBITDA Margin over 5 years is 1466.55%, with a median of 1040.46% recorded in 2024.
  • The sharpest move saw EBITDA Margin tumbled -523486bps in 2023, then skyrocketed 507721bps in 2024.
  • Year by year, EBITDA Margin stood at 406.06% in 2021, then skyrocketed by 69bps to 123.92% in 2022, then plummeted by -2000bps to 2601.91% in 2023, then fell by -9bps to 2834.41% in 2024, then increased by 16bps to 2367.49% in 2025.
  • Business Quant data shows EBITDA Margin for FATE at 2367.49% in Q4 2025, 1847.16% in Q3 2025, and 1793.34% in Q2 2025.